OnKure Therapeutics, Inc. 8-K

What Happened On March 27, 2026, OnKure Therapeutics, Inc. announced a securities purchase agreement for a private placement expected to close March 31, 2026, that would raise approximately $150.0 million in gross proceeds. The financing will issue 26,713,636 shares of Class A common stock at $4.15 per share and pre-funded warrants to purchase 9,430,959 shares at $4.1499 per underlying Warrant Share. As part of the transaction, lead investor AI Biotechnology LLC has the right to designate a board nominee; the Board elected Dr. Liam Ratcliffe as a Class I director effective contingent on closing. The company also filed a Registration Rights Agreement to register the resale of the offered securities and agreed to customary lock-ups for executives and directors.

Key Details

• Financing: ~26.7M shares at $4.15 and pre-funded warrants for 9.43M shares for aggregate gross proceeds of about $150.0M (before fees/expenses).
• Closing & filing: Private Placement expected to close March 31, 2026; registration statement to be filed within 30 days after closing with effectiveness deadlines described in the filing.
• Governance: AI Biotechnology LLC (Lead Investor) can designate a board nominee while retaining at least 50% of its purchased securities; Dr. Liam Ratcliffe was elected contingent on closing.
• Clinical updates: OnKure plans IND submissions for next-gen PI3Kα pan‑mutant candidates OKI-345 and OKI-355 in H1 2027; PIKture-01 (OKI-219) completed certain dose-escalation cohorts (single-agent n=38; OKI-219+fulvestrant n=33); company does not plan further independent development of OKI-219 for now and expects to present mature PIKture-01 data by year-end.

Why It Matters This transaction, if completed, would provide OnKure with a significant cash infusion intended to fund preclinical and clinical development of its next‑generation PI3Kα programs (OKI-345 and OKI-355) and support working capital. The deal also creates immediate potential dilution (shares issued plus pre-funded warrants exercisable for nominal price) and places a lead investor representative on the board, which could affect oversight and strategy. Investors should note the company’s updated clinical priorities (shifting away from independent OKI-219 development) and the registration and lock-up terms that govern resale and timing of investor sales as disclosed in the 8-K.